Texas court keeps compounding pharmacy's antitrust case against Novo and Lilly closed
A federal judge refused compounder Strive Specialties' request to revive its already-dismissed claim that Novo Nordisk and Eli Lilly stifled GLP-1 competition. The piece notes HSBC trimmed its Novo price target to DKK 280 as investors weigh a strong Wegovy pill launch against softer 2026 forecasts.
Source: ad-hoc-news (24 Oct 2026).